A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder cancer.

•Bacillus Calmette-Guerin (BCG) is a valuable immunotherapeutic adjunct in the management of non–muscle-invasive bladder cancer.•Dose modification of BCG depends on factors that predict aggressiveness of the tumor and according to individual tolerance.•Both 80 and 120 mg doses of BCG Moscow I, Russian strain are effective and safe for the treatment of non–muscle-invasive bladder cancer.